Toxicity and morbidity of isolated limb perfusion.
Identifieur interne : 012897 ( Main/Exploration ); précédent : 012896; suivant : 012898Toxicity and morbidity of isolated limb perfusion.
Auteurs : B C Vrouenraets [Pays-Bas] ; J M Klaase ; O E Nieweg ; B B KroonSource :
- Seminars in surgical oncology [ 8756-0437 ]
Descripteurs français
- KwdFr :
- Antinéoplasiques alcoylants (administration et posologie), Antinéoplasiques alcoylants (effets indésirables), Facteur de nécrose tumorale alpha (administration et posologie), Facteur de nécrose tumorale alpha (effets indésirables), Facteurs de risque, Humains, Hyperthermie provoquée, Melphalan (administration et posologie), Melphalan (effets indésirables), Membres, Morbidité, Mélanome (traitement médicamenteux), Perfusion régionale de chimiothérapie anticancéreuse (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Tumeurs cutanées (traitement médicamenteux).
- MESH :
- administration et posologie : Antinéoplasiques alcoylants, Facteur de nécrose tumorale alpha, Melphalan.
- effets indésirables : Antinéoplasiques alcoylants, Facteur de nécrose tumorale alpha, Melphalan, Perfusion régionale de chimiothérapie anticancéreuse, Protocoles de polychimiothérapie antinéoplasique.
- traitement médicamenteux : Mélanome, Tumeurs cutanées.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Facteurs de risque, Humains, Hyperthermie provoquée, Membres, Morbidité.
English descriptors
- KwdEn :
- Antineoplastic Agents, Alkylating (administration & dosage), Antineoplastic Agents, Alkylating (adverse effects), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Chemotherapy, Cancer, Regional Perfusion (adverse effects), Extremities, Humans, Hyperthermia, Induced, Melanoma (drug therapy), Melphalan (administration & dosage), Melphalan (adverse effects), Morbidity, Risk Factors, Skin Neoplasms (drug therapy), Tumor Necrosis Factor-alpha (administration & dosage), Tumor Necrosis Factor-alpha (adverse effects).
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Alkylating, Melphalan, Tumor Necrosis Factor-alpha.
- chemical , adverse effects : Antineoplastic Agents, Alkylating, Melphalan, Tumor Necrosis Factor-alpha.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Cancer, Regional Perfusion.
- drug therapy : Melanoma, Skin Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Extremities, Humans, Hyperthermia, Induced, Morbidity, Risk Factors.
Abstract
Because a relationship between toxicity and treatment outcome has never been demonstrated for isolated limb perfusion (ILP) with melphalan, it is important to keep the side-effects of the procedure restricted to a minimum. Risk factors for more severe acute regional toxicity have recently been identified with tissue temperature above 40 degrees C and a high melphalan peak concentration being the most important. Acute regional toxicity should be mild taking into account these factors and maintaining the normal physiological conditions in the limb during ILP. This should also decrease the incidence of long-term morbidity, especially ankle stiffness and muscle atrophy, since a relation between the severity of the acute regional tissue reactions and long-term morbidity has been demonstrated. Lymphedema is strongly linked to a concomitant regional lymph node dissection and this operation may be delayed until the acute regional tissue reactions have faded. It is not yet clear whether the addition of tumor necrosis factor-alpha (TNF-alpha) to melphalan increases regional toxicity. In the absence of melphalan leakage to the systemic circulation, systemic toxicity is minimal; this is also true with TNF-alpha. Compared to ILP with melphalan +/- TNF-alpha, ILP with other drugs is less effective and often is associated with increased regional toxicity.
PubMed: 9548605
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004F10
- to stream PubMed, to step Curation: 004F10
- to stream PubMed, to step Checkpoint: 004F10
- to stream Ncbi, to step Merge: 00BB61
- to stream Ncbi, to step Curation: 00BB61
- to stream Ncbi, to step Checkpoint: 00BB61
- to stream Main, to step Merge: 013B13
- to stream Main, to step Curation: 012897
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toxicity and morbidity of isolated limb perfusion.</title><author><name sortKey="Vrouenraets, B C" sort="Vrouenraets, B C" uniqKey="Vrouenraets B" first="B C" last="Vrouenraets">B C Vrouenraets</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek ziekenhuis), Amsterdam.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName><wicri:orgArea>Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek ziekenhuis)</wicri:orgArea></affiliation></author><author><name sortKey="Klaase, J M" sort="Klaase, J M" uniqKey="Klaase J" first="J M" last="Klaase">J M Klaase</name></author><author><name sortKey="Nieweg, O E" sort="Nieweg, O E" uniqKey="Nieweg O" first="O E" last="Nieweg">O E Nieweg</name></author><author><name sortKey="Kroon, B B" sort="Kroon, B B" uniqKey="Kroon B" first="B B" last="Kroon">B B Kroon</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1998 Apr-May</MedlineDate></PubDate></date><idno type="RBID">pubmed:9548605</idno><idno type="pmid">9548605</idno><idno type="wicri:Area/PubMed/Corpus">004F10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004F10</idno><idno type="wicri:Area/PubMed/Curation">004F10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004F10</idno><idno type="wicri:Area/PubMed/Checkpoint">004F10</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004F10</idno><idno type="wicri:Area/Ncbi/Merge">00BB61</idno><idno type="wicri:Area/Ncbi/Curation">00BB61</idno><idno type="wicri:Area/Ncbi/Checkpoint">00BB61</idno><idno type="wicri:doubleKey">8756-0437::Vrouenraets B:toxicity:and:morbidity</idno><idno type="wicri:Area/Main/Merge">013B13</idno><idno type="wicri:Area/Main/Curation">012897</idno><idno type="wicri:Area/Main/Exploration">012897</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Toxicity and morbidity of isolated limb perfusion.</title><author><name sortKey="Vrouenraets, B C" sort="Vrouenraets, B C" uniqKey="Vrouenraets B" first="B C" last="Vrouenraets">B C Vrouenraets</name><affiliation wicri:level="3"><nlm:affiliation>Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek ziekenhuis), Amsterdam.</nlm:affiliation><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName><wicri:orgArea>Department of Surgery, The Netherlands Cancer Institute (Antoni van Leeuwenhoek ziekenhuis)</wicri:orgArea></affiliation></author><author><name sortKey="Klaase, J M" sort="Klaase, J M" uniqKey="Klaase J" first="J M" last="Klaase">J M Klaase</name></author><author><name sortKey="Nieweg, O E" sort="Nieweg, O E" uniqKey="Nieweg O" first="O E" last="Nieweg">O E Nieweg</name></author><author><name sortKey="Kroon, B B" sort="Kroon, B B" uniqKey="Kroon B" first="B B" last="Kroon">B B Kroon</name></author></analytic><series><title level="j">Seminars in surgical oncology</title><idno type="ISSN">8756-0437</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents, Alkylating (administration & dosage)</term><term>Antineoplastic Agents, Alkylating (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Chemotherapy, Cancer, Regional Perfusion (adverse effects)</term><term>Extremities</term><term>Humans</term><term>Hyperthermia, Induced</term><term>Melanoma (drug therapy)</term><term>Melphalan (administration & dosage)</term><term>Melphalan (adverse effects)</term><term>Morbidity</term><term>Risk Factors</term><term>Skin Neoplasms (drug therapy)</term><term>Tumor Necrosis Factor-alpha (administration & dosage)</term><term>Tumor Necrosis Factor-alpha (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques alcoylants (administration et posologie)</term><term>Antinéoplasiques alcoylants (effets indésirables)</term><term>Facteur de nécrose tumorale alpha (administration et posologie)</term><term>Facteur de nécrose tumorale alpha (effets indésirables)</term><term>Facteurs de risque</term><term>Humains</term><term>Hyperthermie provoquée</term><term>Melphalan (administration et posologie)</term><term>Melphalan (effets indésirables)</term><term>Membres</term><term>Morbidité</term><term>Mélanome (traitement médicamenteux)</term><term>Perfusion régionale de chimiothérapie anticancéreuse (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Tumeurs cutanées (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents, Alkylating</term><term>Melphalan</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents, Alkylating</term><term>Melphalan</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques alcoylants</term><term>Facteur de nécrose tumorale alpha</term><term>Melphalan</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Chemotherapy, Cancer, Regional Perfusion</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Melanoma</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques alcoylants</term><term>Facteur de nécrose tumorale alpha</term><term>Melphalan</term><term>Perfusion régionale de chimiothérapie anticancéreuse</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Mélanome</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Extremities</term><term>Humans</term><term>Hyperthermia, Induced</term><term>Morbidity</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term><term>Humains</term><term>Hyperthermie provoquée</term><term>Membres</term><term>Morbidité</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Because a relationship between toxicity and treatment outcome has never been demonstrated for isolated limb perfusion (ILP) with melphalan, it is important to keep the side-effects of the procedure restricted to a minimum. Risk factors for more severe acute regional toxicity have recently been identified with tissue temperature above 40 degrees C and a high melphalan peak concentration being the most important. Acute regional toxicity should be mild taking into account these factors and maintaining the normal physiological conditions in the limb during ILP. This should also decrease the incidence of long-term morbidity, especially ankle stiffness and muscle atrophy, since a relation between the severity of the acute regional tissue reactions and long-term morbidity has been demonstrated. Lymphedema is strongly linked to a concomitant regional lymph node dissection and this operation may be delayed until the acute regional tissue reactions have faded. It is not yet clear whether the addition of tumor necrosis factor-alpha (TNF-alpha) to melphalan increases regional toxicity. In the absence of melphalan leakage to the systemic circulation, systemic toxicity is minimal; this is also true with TNF-alpha. Compared to ILP with melphalan +/- TNF-alpha, ILP with other drugs is less effective and often is associated with increased regional toxicity.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country><region><li>Hollande-Septentrionale</li></region><settlement><li>Amsterdam</li></settlement></list><tree><noCountry><name sortKey="Klaase, J M" sort="Klaase, J M" uniqKey="Klaase J" first="J M" last="Klaase">J M Klaase</name><name sortKey="Kroon, B B" sort="Kroon, B B" uniqKey="Kroon B" first="B B" last="Kroon">B B Kroon</name><name sortKey="Nieweg, O E" sort="Nieweg, O E" uniqKey="Nieweg O" first="O E" last="Nieweg">O E Nieweg</name></noCountry><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Vrouenraets, B C" sort="Vrouenraets, B C" uniqKey="Vrouenraets B" first="B C" last="Vrouenraets">B C Vrouenraets</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 012897 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 012897 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9548605
|texte= Toxicity and morbidity of isolated limb perfusion.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9548605" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |